Journal: Critical Care Explorations

Article Title: Surfactant Protein D Influences Mortality During Abdominal Sepsis by Facilitating Escherichia coli Colonization in the Gut

doi: 10.1097/CCE.0000000000000699

Figure Lengend Snippet: Surfactant protein D (SPD) is synthesized by the gallbladder and promotes colonization of both the cecum and colon with Escherichia coli . A , SPD +/+ gut organs were harvested at baseline or post-cecal ligation and puncture (CLP) with Western blots performed for SPD or β -actin (loading control). Blots represent pooled samples, n = 2/group. Representative gel shown from three experiments. Lungs from SPD −/− and SPD +/+ mice were used as negative and positive controls, respectively. B , Gallbladder was isolated from SPD +/+ mice after CLP or sham surgery and from SPD −/− mice after CLP with Western blots performed for SPD or glyceraldehyde 3-phosphate dehydrogenase antibody (GAPDH; loading control). Blots represent pooled samples, n = 5–7/group. Lungs from SPD −/− mice and SPD +/+ were used as negative and positive controls, respectively. C , SPD −/− mice ( n = 9) were gavaged with recombinant surfactant protein D (rSPD), followed by gavage with green fluorescent protein (GFP)-labeled E. coli , and compared with SPD −/− mice gavaged only with GFP-labeled E. coli ( n = 9). After 24 hr, cecum and colon were harvested. GFP-labeled E. coli were then detected by culture (Mann-Whitney * p < 0.05, ** p < 0.01). CFU = colony forming units.

Article Snippet: SPD +/+ and SPD −/− mice were gavaged with 10 μL/g of ampicillin-resistant GFP-labeled E. coli (ATCC 25922GFP, 3.74 × 10 8 colony forming units/mL) with or without recombinant human surfactant protein D (rSPD) (Cat 1920-SP-050, R&D systems).

Techniques: Synthesized, Ligation, Western Blot, Control, Isolation, Recombinant, Labeling, MANN-WHITNEY

Journal: Journal of Cancer

Article Title: Knockdown of HOXD13 in Oral Squamous Cell Carcinoma Inhibited its Proliferation, Migration, and Influenced Fatty Acid Metabolism

doi: 10.7150/jca.102100

Figure Lengend Snippet: A: Volcano plot showing differentially expressed genes (DEGs) in TCGA-OSCC. Upregulated genes are indicated in red, and downregulated genes are in cyan. B: Volcanic plot of DEGs in GSE23558 with similar color coding for upregulated (red) and downregulated (cyan) genes. C: Volcano plot of DEGs in GSE37991, with upregulated genes highlighted in red and downregulated genes in cyan. D: Venn diagram illustrating the intersection of 121 upregulated DEGs from TCGA, GSE23558, and GSE37991 datasets. E: Gene Ontology (GO) enrichment analysis of the 121 upregulated DEGs. F: KEGG pathway enrichment analysis of the 121 upregulated DEGs. G: Identification of top 10 hub genes. H-Q: Receiver Operating Characteristic (ROC) curves and Area Under the Curve (AUC) values for FOXM1, CSF2, BIRC5, HOXD13, MMP9, SPP1, CXCL9, CXCL11, FN1, and FOXA2.

Article Snippet: Antibodies used included HOXD13 (Proteintech No.18736-1-AP), β-tubulin (Proteintech No: CL488-66240), CPT2 (Abways CY5699), ACOX3 (HUABIO ER60440), ACADVL (Abways CY8651), ECHS1 (Proteintech, No. 66117-1-Ig), HADHA (Proteintech, No. 60250-1-Ig), and GAPDH (Abways, AB2000).

Techniques:

Journal: Journal of Cancer

Article Title: Knockdown of HOXD13 in Oral Squamous Cell Carcinoma Inhibited its Proliferation, Migration, and Influenced Fatty Acid Metabolism

doi: 10.7150/jca.102100

Figure Lengend Snippet: A-J: RT-qPCR analysis showing tissue expression levels of FOXM1, CSF2, BIRC5, HOXD13, MMP9, SPP1, CXCL9, CXCL11, FN1 and FOXA2. K-T: Gene expression validation in four OSCC cell lines (CAL-27, SCC-4, SCC-9, SCC-25) and the normal oral epithelial cell line HOK, using RT-qPCR. GAPDH was used as an internal reference gene. Data are shown as mean ± standard deviation (SD), with statistical analysis performed using a two-tailed unpaired t-test (n = 3 independent experiments). (*P < 0.05, **P < 0.01, ***P < 0.001).

Article Snippet: Antibodies used included HOXD13 (Proteintech No.18736-1-AP), β-tubulin (Proteintech No: CL488-66240), CPT2 (Abways CY5699), ACOX3 (HUABIO ER60440), ACADVL (Abways CY8651), ECHS1 (Proteintech, No. 66117-1-Ig), HADHA (Proteintech, No. 60250-1-Ig), and GAPDH (Abways, AB2000).

Techniques: Quantitative RT-PCR, Expressing, Gene Expression, Biomarker Discovery, Standard Deviation, Two Tailed Test

Journal: Journal of Cancer

Article Title: Knockdown of HOXD13 in Oral Squamous Cell Carcinoma Inhibited its Proliferation, Migration, and Influenced Fatty Acid Metabolism

doi: 10.7150/jca.102100

Figure Lengend Snippet: A: Correlation between HOXD13 expression levels and the relative abundance of 24 immune cell types; B: Volcano plot based on median HOXD13 expression levels in the TCGA dataset; C-M: Scatter plots showing the correlation between HOXD13 expression and various immune cell types.

Article Snippet: Antibodies used included HOXD13 (Proteintech No.18736-1-AP), β-tubulin (Proteintech No: CL488-66240), CPT2 (Abways CY5699), ACOX3 (HUABIO ER60440), ACADVL (Abways CY8651), ECHS1 (Proteintech, No. 66117-1-Ig), HADHA (Proteintech, No. 60250-1-Ig), and GAPDH (Abways, AB2000).

Techniques: Expressing

Journal: Journal of Cancer

Article Title: Knockdown of HOXD13 in Oral Squamous Cell Carcinoma Inhibited its Proliferation, Migration, and Influenced Fatty Acid Metabolism

doi: 10.7150/jca.102100

Figure Lengend Snippet: A: Lentiviral transduction of SCC-9 and CAL-27 cell lines with HOXD13 knockdown constructs. B-C: qRT-PCR analysis confirming HOXD13 expression levels in three knockdown groups versus control in SCC-9 and CAL-27 cell lines. D: Western blot analysis of HOXD13 protein expression in SCC-9 and CAL-27 cells. Data are expressed as mean ± standard deviation (SD), with statistical significance determined by two-tailed unpaired t-tests (n = 3 independent experiments). (* P < 0.05, **P < 0.01, ***P < 0.001).

Article Snippet: Antibodies used included HOXD13 (Proteintech No.18736-1-AP), β-tubulin (Proteintech No: CL488-66240), CPT2 (Abways CY5699), ACOX3 (HUABIO ER60440), ACADVL (Abways CY8651), ECHS1 (Proteintech, No. 66117-1-Ig), HADHA (Proteintech, No. 60250-1-Ig), and GAPDH (Abways, AB2000).

Techniques: Transduction, Knockdown, Construct, Quantitative RT-PCR, Expressing, Control, Western Blot, Standard Deviation, Two Tailed Test

Journal: Journal of Cancer

Article Title: Knockdown of HOXD13 in Oral Squamous Cell Carcinoma Inhibited its Proliferation, Migration, and Influenced Fatty Acid Metabolism

doi: 10.7150/jca.102100

Figure Lengend Snippet: D: CCK-8 and EdU assays assessing cell proliferation in SCC-9 and CAL-27 cell lines with HOXD13 knockdown compared to control. E-G: wound healing assays and transwell migration tests evaluating cell migration ability in HOXD13 knockdown groups versus control in SCC-9 and CAL-27 cell lines. Results are presented as mean ± standard deviation (SD) with statistical analysis determined by two-tailed unpaired t-tests (n = 3 independent experiments). (*P < 0.05, **P < 0.01, ***P < 0.001).

Article Snippet: Antibodies used included HOXD13 (Proteintech No.18736-1-AP), β-tubulin (Proteintech No: CL488-66240), CPT2 (Abways CY5699), ACOX3 (HUABIO ER60440), ACADVL (Abways CY8651), ECHS1 (Proteintech, No. 66117-1-Ig), HADHA (Proteintech, No. 60250-1-Ig), and GAPDH (Abways, AB2000).

Techniques: CCK-8 Assay, Knockdown, Control, Migration, Standard Deviation, Two Tailed Test

Journal: Journal of Cancer

Article Title: Knockdown of HOXD13 in Oral Squamous Cell Carcinoma Inhibited its Proliferation, Migration, and Influenced Fatty Acid Metabolism

doi: 10.7150/jca.102100

Figure Lengend Snippet: A: Prognostic analysis map of HOXD13 in TCGA dataset. B: Gene Set Enrichment Analysis (GSEA) results showing enrichment of lipid metabolism-related pathways in high versus low HOXD13 expression groups. C: Heatmap of proteomic sequencing data showing DEG expression in CAL-27 cells with HOXD13 knockdown compared to control. D-E: KEGG enrichment analysis of differentially expressed proteins, highlighting fatty acid degradation pathways. F: Protein expression levels of CPT2, ACOX3, ACADVL, ECHS1, and HADHA in CAL-27 cells post-HOXD13 knockdown. G: Validation of protein expression levels of CPT2, ACOX3, ACADVL, ECHS1, and HADHA in SCC-9 and CAL-27 cell lines.

Article Snippet: Antibodies used included HOXD13 (Proteintech No.18736-1-AP), β-tubulin (Proteintech No: CL488-66240), CPT2 (Abways CY5699), ACOX3 (HUABIO ER60440), ACADVL (Abways CY8651), ECHS1 (Proteintech, No. 66117-1-Ig), HADHA (Proteintech, No. 60250-1-Ig), and GAPDH (Abways, AB2000).

Techniques: Expressing, Sequencing, Knockdown, Control, Biomarker Discovery